Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd.

NASDAQ:ENLV

Overview | Financials
Company Name Enlivex Therapeutics Ltd.
Symbol ENLV
Currency USD
Price 1.355
Market Cap 28,281,289
Dividend Yield 0%
52-week-range 1.15 - 4.59
Industry Biotechnology
Sector Healthcare
CEO Mr. Shai Novik M.B.A.
Website https://www.enlivex.com

An error occurred while fetching data.

About Enlivex Therapeutics Ltd.

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in

Related Stocks

Synlogic, Inc. logo

Synlogic, Inc.

SYBX

1.55 USD

LENSAR, Inc. logo

LENSAR, Inc.

LNSR

4.92 USD

Homology Medicines, Inc. logo

Homology Medicines, Inc.

FIXX

0.935 USD

eFFECTOR Therapeutics, Inc. logo

eFFECTOR Therapeutics, Inc.

EFTR

0.055 USD

Eliem Therapeutics, Inc. logo

Eliem Therapeutics, Inc.

ELYM

7.3 USD

Clearside Biomedical, Inc. logo

Clearside Biomedical, Inc.

CLSD

1.17 USD

Longboard Pharmaceuticals, Inc. logo

Longboard Pharmaceuticals, Inc.

LBPH

35.95 USD

Financials

Numbers are in millions USD

Numbers are in millions USD